Log In
Print
BCIQ
Print
Print this Print this
 

UCART19

  Manage Alerts
Collapse Summary General Information
Company Cellectis S.A.
DescriptionChimeric antigen receptor (CAR)-modified CD19-targeted allogeneic T cells
Molecular Target CD19
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPreclinical
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat chronic lymphocytic leukemia (CLL)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$850.0M

$10.0M

$840.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today